Aslan Pharma gets global rights for ASLAN003 compound

6 January 2016

Singapore-based biotech firm Aslan Pharmaceuticals (Nasdaq: ARRY) on Wednesday said under a new agreement with partner Spanish pharma company Almirall (ALM: MC) it now has gained rights to develop and market its compound ASLAN003.

Under the terms of the broadened deal, Almirall has granted Aslan global rights to develop and market ASLAN003 for all non-topical and non-dermatological indications including oncology.

Dr Mark McHale, chief operating officer of Aslan, said: “ASLAN003 is an exciting compound and the promising preclinical data we have observed in various tumor models suggest that it has the potential to become an important novel therapy in the emerging area of cancer metabolism with application to a range of different tumor types. This broadened agreement is a strong endorsement of the success of our collaborative work with Almirall to date and is reflective of both teams’ confidence in each other’s complementary expertise in the research and development of new medicines.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK